Mon, Dec 22, 2014, 12:33 PM EST - U.S. Markets close in 3 hrs 27 mins


% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • johnpapas893 johnpapas893 Oct 15, 2012 7:50 PM Flag

    S&P coverage, PT $105

    On October 11, S&P initiated coverage of ONXX with a buy rating and PT $105.

    We project revenues of $331 million in 2012 and $566 million in 2013, with latter period growth driven by the July 2012 FDA approval of Kyprolis for relapsed multiple myeloma. Although it is a more mature product, we think Nexavar, partnered wth Bayer, could see a boost in sales gowth upon a positive phase III outcome in thyroid cancer, for which data is expected in late 2012.We expect earlier Kyprolis use to drive long-term growth.
    Our 12-month target price of $105 is based on our net present value of ONXX's currently marketed
    drug roster and clinical pipeline. We #$%$ a 16% blended risk discount rate, and estimate peak annual global sales of Kyprolis of more than $2 billion, reflecting our view of favorable label expansion prospects.

    Sentiment: Strong Buy

124.700.0000(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.